Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 25, 2025
Feroot Launches PaymentGuard AI: Automated PCI DSS 4 Compliance for Websites with E-commerce Payment Webpages.
EIN Presswire
·
March 25, 2025
PaymentGuard AI by Feroot Security: Automating PCI DSS 4 Compliance with Requirements 6.4.3 and 11.6.1 for SAQ D and SAQ A-EP E-Commerce Merchants. TORONTO, CANADA, March 25, 2025 /EINPresswire.com/ -- Feroot Security, a leader in cybersecurity …
PUSH for Empowered Pregnancy Launches #MomentForStillness to Honor Babies Born Still and Demand Urgent Action
EIN Presswire
·
March 25, 2025
A Nationwide Call to Address Preventable Stillbirths Begins March 25th at Noon ET NEW YORK, NY, UNITED STATES, March 25, 2025 /EINPresswire.com/ -- PUSH for Empowered Pregnancy is launching the #MomentForStillness campaign at noon ET on Tuesday, March …
Dr. Thierry Jacquemin Expands His Innovative Approach to Health, Performance, and Aesthetic Wellness
GlobeNewswire
·
March 25, 2025
MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- As demand for personalized, science-backed wellness solutions continues to rise, Dr. Thierry Jacquemin is expanding his services to offer advanced treatments in health optimization, anti-aging, and performance …
TravelingWiki Foundation Launches 'Card For a Cause' to Leverage Sports Cards for Free Non Visible Disability Resources
EIN Presswire
·
March 25, 2025
TravelingWiki Now Offers Free Resources in English, Spanish, French, German, Mandarin, Japanese, Hebrew, Arabic, Portuguese, Hindi, Twi, Vietnamese …
PhenoBiome Welcomes New Leadership and Validates Breakthrough Microbiome Modulation
EIN Presswire
·
March 25, 2025
Brian Russon Named CEO, Kait Mikes Appointed COO as Company Advances Clinical Validation of Predictive Platform PALM SPRINGS, CA, UNITED STATES, March 25, 2025 /EINPresswire.com/ -- PhenoBiome, Inc., a pioneering leader in personalized microbiome …
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 25, 2025
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it …
Florida Mesothelioma Victims Center Has Endorsed the Gori Law Firm for a Former Power Plant Worker with Just Diagnosed Mesothelioma or Lung Cancer in Florida-Hire Better Attorneys-Get Better Compensation Results
EIN Presswire
·
March 25, 2025
TAMPA , FL, UNITED STATES, March 25, 2025 /EINPresswire.com/ -- The Florida Mesothelioma Victims Center says, "We have endorsed, and we highly recommend the Gori Law Firm for a former power plant worker with just diagnosed mesothelioma or lung cancer …
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
GlobeNewswire
·
March 25, 2025
New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the …
Theratechnologies reçoit l’approbation de la FDA pour EGRIFTA WR(MC) (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie
GlobeNewswire
·
March 25, 2025
Une nouvelle formulation améliorée remplacera EGRIFTA SVMD MONTRÉAL, 25 mars 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a annoncé …
OmnySense to Target Oncology Patients as Initial Focus for Its Transformative Personal Health-Assessment Solution
EIN Presswire
·
March 25, 2025
19m Americans have cancer. Unplanned acute visits drive nearly half the costs-creating a major unmet need and opportunity for innovative solutions TEL AVIV, ISRAEL, March 25, 2025 /EINPresswire.com/ -- OmnySense, an innovative digital health company …
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
GlobeNewswire
·
March 25, 2025
Marseille, France, March 25, 2025 4:30 p.m. EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized Phase I/II study EVICTION at the American Association for Cancer Research (AACR) Annual …
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
GlobeNewswire
·
March 25, 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts …
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
GlobeNewswire
·
March 25, 2025
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non- …
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
March 25, 2025
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad …
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
GlobeNewswire
·
March 25, 2025
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, …
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
GlobeNewswire
·
March 25, 2025
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for …
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
March 25, 2025
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical data for IO170 add …
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
GlobeNewswire
·
March 25, 2025
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/ …
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
GlobeNewswire
·
March 25, 2025
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
March 25, 2025
WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster …